Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment

Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.

Biogen Discontinues Ionis Collaboration on ALS and Angelman Syndrome Treatments Following Early Clinical Results

Biogen, Ionis, ALS, Angelman Syndrome, collaboration, discontinuation, early-stage readouts, clinical trials, treatments, neurological disorders.